Market closedNon-fractional
Annovis Bio/ANVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Annovis Bio
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Ticker
ANVS
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology
Headquarters
Malvern, United States
Employees
11
Website
www.annovisbio.com
Annovis Bio Metrics
BasicAdvanced
$117M
Market cap
-
P/E ratio
-$5.63
EPS
1.76
Beta
-
Dividend rate
Price and volume
Market cap
$117M
Beta
1.76
Financial strength
Current ratio
1.604
Quick ratio
0.644
Management effectiveness
Return on assets (TTM)
-160.65%
Return on equity (TTM)
-566.49%
Valuation
Price to book
-34.91
Price to tangible book (TTM)
-34.91
Price to free cash flow (TTM)
-2.851
Growth
Earnings per share change (TTM)
54.14%
3-year earnings per share growth (CAGR)
67.54%
What the Analysts think about Annovis Bio
Analyst Ratings
Majority rating from 5 analysts.
Annovis Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$1M
-95.50%
Profit margin
0.00%
NaN%
Annovis Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.07
-$1.63
-$2.24
-$0.72
-
Expected
-$1.14
-$1.09
-$1.30
-$0.80
-$0.47
Surprise
-6.28%
49.50%
71.71%
-9.85%
-
Annovis Bio News
AllArticlesVideos
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
GlobeNewsWire·3 days ago
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Annovis Bio stock?
Annovis Bio (ANVS) has a market cap of $117M as of July 27, 2024.
What is the P/E ratio for Annovis Bio stock?
The price to earnings (P/E) ratio for Annovis Bio (ANVS) stock is 0 as of July 27, 2024.
Does Annovis Bio stock pay dividends?
No, Annovis Bio (ANVS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Annovis Bio dividend payment date?
Annovis Bio (ANVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Annovis Bio?
Annovis Bio (ANVS) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Annovis Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.